News

New research confirms agreement with 7 standard field imaging

FDA decision changes scope of healthcare delivery; increases patient access to early detection of DR

Fifteen fellows, residents showed just why research in retina is on the cutting edge

Investigators optimistic about sustained-release ranibizumab delivery based on phase II LADDER study

Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the OIS@AAO meeting in Chicago, Oct. 2018.

Novel local corticosteroid therapy shows positive efficacy signals, favorable safety profile says Rahul Khurana, MD.

Patients tolerate therapy well; high safety profile allows re-treatment as necessary